Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be evaluated in depth.
Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Viatris stock has no real catalysts; greater downside risk: analysts
Viatris Inc's lack of discernable catalysts and greater downside risk is likely to weigh on the company's share price, according to BofA Securities analysts. In an update to clients, they downgra...
Viatris: Get Paid 5%, Before Growth Materializes
VTRS lost its Humira biosimilar through the divestiture of its biosimilar segment to Biocon, with the former similarly losing another growth prospects in Wegovy.
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
Viatris is advancing in its plan to become leaner and pay off its debt. To do so, it's offloading a trio of non-core business segments.
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
PITTSBURGH , Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets...
Drugmaker Viatris to divest some of its businesses
Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Active Pharmaceutical Ingredients (API) business. It...
Could Viatris Stock Help You Become a Millionaire?
Viatris has a broad business that gives it many growth opportunities to pursue. The company is focusing on launching many products that can generate billions in revenue in the future.
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
Why 5%-Yielding Viatris Hasn't Doubled Yet
Viatris is a healthcare corporation formed through a merger, with a diversified global portfolio and a focus on ophthalmology, gastrointestinal, and dermatology therapeutic areas. Despite its eleva...
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids
Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross
From a technical perspective, Viatris Inc. (VTRS) is looking like an interesting pick, as it just reached a key level of support. VTRS's 50-day simple moving average crossed above its 200-day simpl...
Where Will Viatris Be in 5 Years?
Viatris' near-term focus now is to reduce its heavy debt load. The company is also simplifying its business through more divestitures.
Related Companies